Heather Hunter
Chief Operating Officer, Rockwell Medical
Replay available
Rockwell Medical, Inc. (NASDAQ: RMTI) Q4 2025 earnings conference call, held 2026-03-26. Replay captured from the company's public earnings webcast.

Chief Operating Officer, Rockwell Medical
President and Chief Executive Officer, Rockwell Medical
Chief Financial Officer, Rockwell Medical
Analyst, Maxim Group
Analyst, H.C. Wainwright
Good morning and welcome to Rockwell Medical's fourth quarter and full year 2025 results conference call and webcast. Please note, this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead. Good morning and thank you for joining us for this update on Rockwell Medical. Joining me on today's conference call are Rockwell Medical's President and Chief Executive Officer, Dr. Mark Strobeck, and Rockwell Medical's Chief Financial Officer, Jesse Neary. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ material, excuse me, factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's annual report on Form 10-K for the year ended December 31, 2025 was filed prior to this call and provides a full analysis of the company's business strategy as well as the compan...